Cargando…

What role does PDL1 play in EMT changes in tumors and fibrosis?

Epithelial-mesenchymal transformation (EMT) plays a pivotal role in embryonic development, tissue fibrosis, repair, and tumor invasiveness. Emerging studies have highlighted the close association between EMT and immune checkpoint molecules, particularly programmed cell death ligand 1 (PDL1). PDL1 ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yun-Chao, Zhang, Yu-Ting, Wang, Yi, Zhao, Ya, He, Li-Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463740/
https://www.ncbi.nlm.nih.gov/pubmed/37649487
http://dx.doi.org/10.3389/fimmu.2023.1226038
_version_ 1785098303098060800
author Zhang, Yun-Chao
Zhang, Yu-Ting
Wang, Yi
Zhao, Ya
He, Li-Jie
author_facet Zhang, Yun-Chao
Zhang, Yu-Ting
Wang, Yi
Zhao, Ya
He, Li-Jie
author_sort Zhang, Yun-Chao
collection PubMed
description Epithelial-mesenchymal transformation (EMT) plays a pivotal role in embryonic development, tissue fibrosis, repair, and tumor invasiveness. Emerging studies have highlighted the close association between EMT and immune checkpoint molecules, particularly programmed cell death ligand 1 (PDL1). PDL1 exerts its influence on EMT through bidirectional regulation. EMT-associated factors, such as YB1, enhance PDL1 expression by directly binding to its promoter. Conversely, PDL1 signaling triggers downstream pathways like PI3K/AKT and MAPK, promoting EMT and facilitating cancer cell migration and invasion. Targeting PDL1 holds promise as a therapeutic strategy for EMT-related diseases, including cancer and fibrosis. Indeed, PDL1 inhibitors, such as pembrolizumab and nivolumab, have shown promising results in clinical trials for various cancers. Recent research has also indicated their potential benefit in fibrosis treatment in reducing fibroblast activation and extracellular matrix deposition, thereby addressing fibrosis. In this review, we examine the multifaceted role of PDL1 in immunomodulation, growth, and fibrosis promotion. We discuss the challenges, mechanisms, and clinical observations related to PDL1, including the limitations of the PD1/PDL1 axis in treatment and PD1-independent intrinsic PDL1 signaling. Our study highlights the dynamic changes in PDL1 expression during the EMT process across various tumor types. Through interplay between PDL1 and EMT, we uncover co-directional alterations, regulatory pathways, and diverse changes resulting from PDL1 intervention in oncology. Additionally, our findings emphasize the dual role of PDL1 in promoting fibrosis and modulating immune responses across multiple diseases, with potential implications for therapeutic approaches. We particularly investigate the therapeutic potential of targeting PDL1 in type II EMT fibrosis: strike balance between fibrosis modulation and immune response regulation. This analysis provides valuable insights into the multifaceted functions of PDL1 and contributes to our understanding of its complex mechanisms and therapeutic implications.
format Online
Article
Text
id pubmed-10463740
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104637402023-08-30 What role does PDL1 play in EMT changes in tumors and fibrosis? Zhang, Yun-Chao Zhang, Yu-Ting Wang, Yi Zhao, Ya He, Li-Jie Front Immunol Immunology Epithelial-mesenchymal transformation (EMT) plays a pivotal role in embryonic development, tissue fibrosis, repair, and tumor invasiveness. Emerging studies have highlighted the close association between EMT and immune checkpoint molecules, particularly programmed cell death ligand 1 (PDL1). PDL1 exerts its influence on EMT through bidirectional regulation. EMT-associated factors, such as YB1, enhance PDL1 expression by directly binding to its promoter. Conversely, PDL1 signaling triggers downstream pathways like PI3K/AKT and MAPK, promoting EMT and facilitating cancer cell migration and invasion. Targeting PDL1 holds promise as a therapeutic strategy for EMT-related diseases, including cancer and fibrosis. Indeed, PDL1 inhibitors, such as pembrolizumab and nivolumab, have shown promising results in clinical trials for various cancers. Recent research has also indicated their potential benefit in fibrosis treatment in reducing fibroblast activation and extracellular matrix deposition, thereby addressing fibrosis. In this review, we examine the multifaceted role of PDL1 in immunomodulation, growth, and fibrosis promotion. We discuss the challenges, mechanisms, and clinical observations related to PDL1, including the limitations of the PD1/PDL1 axis in treatment and PD1-independent intrinsic PDL1 signaling. Our study highlights the dynamic changes in PDL1 expression during the EMT process across various tumor types. Through interplay between PDL1 and EMT, we uncover co-directional alterations, regulatory pathways, and diverse changes resulting from PDL1 intervention in oncology. Additionally, our findings emphasize the dual role of PDL1 in promoting fibrosis and modulating immune responses across multiple diseases, with potential implications for therapeutic approaches. We particularly investigate the therapeutic potential of targeting PDL1 in type II EMT fibrosis: strike balance between fibrosis modulation and immune response regulation. This analysis provides valuable insights into the multifaceted functions of PDL1 and contributes to our understanding of its complex mechanisms and therapeutic implications. Frontiers Media S.A. 2023-08-15 /pmc/articles/PMC10463740/ /pubmed/37649487 http://dx.doi.org/10.3389/fimmu.2023.1226038 Text en Copyright © 2023 Zhang, Zhang, Wang, Zhao and He https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Yun-Chao
Zhang, Yu-Ting
Wang, Yi
Zhao, Ya
He, Li-Jie
What role does PDL1 play in EMT changes in tumors and fibrosis?
title What role does PDL1 play in EMT changes in tumors and fibrosis?
title_full What role does PDL1 play in EMT changes in tumors and fibrosis?
title_fullStr What role does PDL1 play in EMT changes in tumors and fibrosis?
title_full_unstemmed What role does PDL1 play in EMT changes in tumors and fibrosis?
title_short What role does PDL1 play in EMT changes in tumors and fibrosis?
title_sort what role does pdl1 play in emt changes in tumors and fibrosis?
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463740/
https://www.ncbi.nlm.nih.gov/pubmed/37649487
http://dx.doi.org/10.3389/fimmu.2023.1226038
work_keys_str_mv AT zhangyunchao whatroledoespdl1playinemtchangesintumorsandfibrosis
AT zhangyuting whatroledoespdl1playinemtchangesintumorsandfibrosis
AT wangyi whatroledoespdl1playinemtchangesintumorsandfibrosis
AT zhaoya whatroledoespdl1playinemtchangesintumorsandfibrosis
AT helijie whatroledoespdl1playinemtchangesintumorsandfibrosis